Also, HUWE1 is frequently deregulated in multiple myeloma (MM) and targeting HUWE1 with the small molecule inhibitors in combination with lenalidomide results in synergistic growth inhibition in MM cells in vitro and in vivo (111). Here, HUWE1 is linked to Miyoshi myopathy.